Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500856PMID: 29999915
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 231277-92-2
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of lapatinib during breastfeeding. Because lapatinib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 24 hours and it might accumulate in the infant. It is also given in combination with capecitabine, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during lapatinib therapy and for 1 week after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Lapatinib
CAS Registry Number
231277-92-2
Drug Class
- Breast Feeding
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Signal Transduction Inhibitors
- Tyrosine Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Vandetanib.[Drugs and Lactation Database (...]Review Vandetanib.. Drugs and Lactation Database (LactMed®). 2006
- Review Gefitinib.[Drugs and Lactation Database (...]Review Gefitinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Sorafenib.[Drugs and Lactation Database (...]Review Sorafenib.. Drugs and Lactation Database (LactMed®). 2006
- Review Erlotinib.[Drugs and Lactation Database (...]Review Erlotinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Vismodegib.[Drugs and Lactation Database (...]Review Vismodegib.. Drugs and Lactation Database (LactMed®). 2006
- Lapatinib - Drugs and Lactation Database (LactMed®)Lapatinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...